Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.

Considering recent findings that both urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitors (PAIs) are involved in tumor growth through an urokinase-type plasminogen activator (uPA) activity-independent mechanism, the relation between the presence of these factors in tumor tissue and the clinicopathologic variables in colorectal carcinoma was reevaluated.
In 100 colorectal carcinoma patients, antigen levels of u-PA, uPAR, and PAI-1 and PAI-2 were assayed in both tumor tissues and their normal counterparts. Plasma levels of soluble uPAR also were determined.
All uPAR, uPA, PAI-1, and PAI-2 antigen levels in tumor tissue were significantly higher than those in normal tissue. Levels of both uPAR and PAI-1 were significantly higher (3.09 +/- 1.37 and 6.63 +/- 7.49, respectively) in large tumors (>/=50 mm in greatest dimension) than those in smaller tumors (< 50 mm) (2.50 +/- 1.07 and 2.72 +/- 2.70, respectively) (P < 0.05). Significant positive correlation coefficients (r) were obtained between tumor size and the calculated ratios of PAI-1/uPAR (r = 0.490; P < 0.0001) and PAI-1/uPA (r = 0. 469; P < 0.0001). In addition to liver metastases (P = 0.004) and lymph node involvement (P = 0.04), high levels of uPAR (P = 0.05) also were found to be of independent prognostic value by multivariate analysis.
Higher expression of uPAR was related to poor prognosis of patients with colorectal carcinoma and excess amounts of PAI-1 over uPAR or uPAR-bound uPA appeared to play an important role in tumor progression.
AuthorsJ Abe, T Urano, H Konno, Y Erhan, T Tanaka, N Nishino, A Takada, S Nakamura
JournalCancer (Cancer) Vol. 86 Issue 12 Pg. 2602-11 (Dec 15 1999) ISSN: 0008-543X [Print] UNITED STATES
PMID10594855 (Publication Type: Journal Article)
CopyrightCopyright 1999 American Cancer Society.
Chemical References
  • PLAUR protein, human
  • Plasminogen Activator Inhibitor 1
  • Plasminogen Activator Inhibitor 2
  • Receptors, Cell Surface
  • Receptors, Urokinase Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
  • Adult
  • Aged
  • Carcinoma (metabolism, pathology, secondary)
  • Colorectal Neoplasms (blood, metabolism, pathology)
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Plasminogen Activator Inhibitor 1 (blood, metabolism)
  • Plasminogen Activator Inhibitor 2 (blood, metabolism)
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Receptors, Cell Surface (blood, metabolism)
  • Receptors, Urokinase Plasminogen Activator
  • Survival Analysis
  • Urokinase-Type Plasminogen Activator (blood, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: